LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Theravance Biopharma Inc

Cerrado

11.25 4.46

Resumen

Variación precio

24h

Actual

Mínimo

11.19

Máximo

11.46

Métricas clave

By Trading Economics

Ingresos

1.9M

-14M

Ventas

-3.4M

15M

BPA

-0.173

Margen de beneficio

-88.244

Empleados

97

EBITDA

-7.5M

-14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+51.11% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

118M

558M

Apertura anterior

6.79

Cierre anterior

11.25

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Theravance Biopharma Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jun 2025, 10:49 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

2 jun 2025, 10:00 UTC

Adquisiciones, fusiones, absorciones

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

Comparación entre iguales

Cambio de precio

Theravance Biopharma Inc Esperado

Precio Objetivo

By TipRanks

51.11% repunte

Estimación a 12 meses

Media 17 USD  51.11%

Máximo 24 USD

Mínimo 12 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Theravance Biopharma Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.77 / 10.39Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.